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NOTCH3 inactivation increases triple
negative breast cancer sensitivity to
geﬁtinib by promoting EGFR tyrosine
dephosphorylation and its intracellular
arrest
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Zein Mersini Besharat 1, Maria Gemma Pignataro5, Alessandra Vacca6, Giulia d’Amati5, Marella Maroder7,
Claudio Talora1, Carlo Capalbo1, Diana Bellavia1 and Saula Checquolo 7
Abstract
Notch dysregulation has been implicated in numerous tumors, including triple-negative breast cancer (TNBC), which is
the breast cancer subtype with the worst clinical outcome. However, the importance of individual receptors in TNBC
and their speciﬁc mechanism of action remain to be elucidated, even if recent ﬁndings suggested a speciﬁc role of
activated-Notch3 in a subset of TNBCs. Epidermal growth factor receptor (EGFR) is overexpressed in TNBCs but the use
of anti-EGFR agents (including tyrosine kinase inhibitors, TKIs) has not been approved for the treatment of these
patients, as clinical trials have shown disappointing results. Resistance to EGFR blockers is commonly reported. Here
we show that Notch3-speciﬁc inhibition increases TNBC sensitivity to the TKI-geﬁtinib in TNBC-resistant cells.
Mechanistically, we demonstrate that Notch3 is able to regulate the activated EGFR membrane localization into lipid
rafts microdomains, as Notch3 inhibition, such as rafts depletion, induces the EGFR internalization and its intracellular
arrest, without involving receptor degradation. Interestingly, these events are associated with the EGFR tyrosine
dephosphorylation at Y1173 residue (but not at Y1068) by the protein tyrosine phosphatase H1 (PTPH1), thus
suggesting its possible involvement in the observed Notch3-dependent TNBC sensitivity response to geﬁtinib.
Consistent with this notion, a nuclear localization defect of phospho-EGFR is observed after combined blockade of
EGFR and Notch3, which results in a decreased TNBC cell survival. Notably, we observed a signiﬁcant correlation
between EGFR and NOTCH3 expression levels by in silico gene expression and immunohistochemical analysis of
human TNBC primary samples. Our ﬁndings strongly suggest that combined therapies of TKI-geﬁtinib with Notch3-
speciﬁc suppression may be exploited as a drug combination advantage in TNBC treatment.
Introduction
Triple-negative breast cancer (TNBC), which lacks
estrogen receptor (ER), progesterone receptor, and
human epidermal growth factor 2 receptor (HER2),
accounts for about 15–20% of breast cancers and repre-
sents the most aggressive breast cancer (BC) subtype1. To
date, no molecularly targeted agents have been approved
for TNBC, leaving to the conventional chemotherapy the
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role of primary option for systemic treatment. Although
TNBC-bearing patients better respond to current che-
motherapy than do non-TNBC ones, patients with TNBC
experience a more rapid relapse evolving as metastatic
disease. For this reason, this BC subtype suffers from the
poorest prognosis1. Therefore, targeted therapeutic stra-
tegies for TNBC are urgently needed.
The overexpression of the tyrosine kinase receptor
epidermal growth factor receptor (EGFR) is a hallmark of
TNBC (45–70%) and exhaustive gene expression proﬁling
has identiﬁed several EGFR-associated poor prognostic
signatures2. Anti-EGFR therapies, including tyrosine
kinase inhibitors (TKIs) and monoclonal antibodies, have
been developed and are already available for treatment of
different cancers such as non-small cell lung cancer
(NSCLC) and colorectal cancer, making EGFR inhibitors
an attractive option for TNBC therapy3. Unfortunately, no
EGFR inhibitory therapies are currently approved for BC
treatment, including TNBC, as results from clinical trials
are disappointing4. This limited clinical activity is often
due to the existence of compensatory pathways that
confer resistance to EGFR inhibition, thus allowing con-
tinued cancer cell growth and survival5–7.
Notch signaling dysregulation is often associated with
tumor transformation8, including the TNBC pathogenesis
and progression9–11. In particular, TNBCs show Notch3
ampliﬁcation and overexpression12,13, and Notch3
knockdown has been shown to reduce the proliferation of
ErbB2-negative breast tumor cells9,14. More recently,
these data have been strongly supported by Choy et al.15
who demonstrated that constitutive Notch3 signaling can
drive an oncogenic program in a subset of TNBCs, thus
suggesting that Notch3 activity (and not others Notch
paralogues) may be clinically relevant in this BC subtype.
There is a growing body of evidence that Notch hyper-
activation or mutation results in several events that enable
BC cells to become resistant to targeted treatments
through different mechanisms16,17, thus suggesting that
the inactivation of Notch signaling could be a potential
therapeutic approach for overcoming resistance to drugs7.
Interestingly, more recently, it has been demonstrated
that Notch3 pathway is strongly involved in the stroma-
mediated expansion of therapy-resistant TNBC cells18.
Notch-EGFR interplay occurs in different cellular con-
texts19,20, including BC16, raising the possibility that
Notch signaling could be involved in the above mentioned
resistance to EGFR inhibition. Arasada et al.21 ﬁrst
reported that the EGFR inhibition by erlotinib treatment
is able to activate Notch signaling in human lung cancer,
resulting in an enriched stem cell-like populations in a
Notch3, but not Notch1-dependent manner. In TNBC, it
has been demonstrated that combined Notch-EGFR
pathway inhibition is a rational treatment strategy for
this type of tumors22. Pan-Notch inhibition using γ-
secretase inhibitor (GSI) treatment supports this conclu-
sion. Unfortunately, the use of GSIs fails to distinguish the
particular Notch receptor driving growth, besides eliciting
severe side effects.
Here we analyze the effects of a selective Notch3 inhi-
bition in the response to geﬁtinib (GEF) treatment of
resistant TNBC cells. We show that Notch3 (but not
Notch1) depletion enhances the therapeutic target activity
of the EGFR, by inducing its dephosphorylation via pro-
tein tyrosine phosphatase H1 (PTPH1), ﬁnally leading to
an increased TNBC sensitivity to TKI-GEF.
Results
Notch3-EGFR correlation in primary TNBC samples
To deepen the understanding of the possible Notch3-
EGFR crosstalk in TNBC context, we ﬁrst performed an in
silico analysis of the NOTCH3 and EGFR gene expression
levels in two cohorts of TNBC patients, collectively con-
sisting of 777 individuals23–26 (Fig. 1a). The summary of
the obtained results (Fig. 1a, upper panel) highlights a
direct correlation between EGFR and NOTCH3 gene
expression levels in both datasets analyzed, while a weaker
correlation between EGFR and NOTCH1 is observed. This
is also evident by the graphs included in the Fig. 1a (lower
Fig. 1 Notch3 and EGFR levels correlate in TNBC primary samples. a Upper panel: summary of the NOTCH3-EGFR and NOTCH1-EGFR gene
expression levels correlation obtained by an in silico analysis from two TNBC tissue arrays (GSE76124 and GSE31519). Lower panels: representative
graphs showing correlation between NOTCH3 (left) or NOTCH1 (right) and EGFR gene expression levels from GSE31519 dataset in a cohort of 579
TNBC patients. In both graphs, each dot corresponds to one patient and the expression value of NOTCH3, NOTCH1, and EGFR is given in log2 scale
after normalizing data with justRMA algorithm normalization. The X–Y axis represent NOTCH3 (left) or NOTCH1 (right) and EGFR (both) expression
levels, respectively. The index Pearson’s R indicated expresses the linear relation between paired samples and P-values were calculated using
Student’s T-test, as described in Material and Methods section. b Upper panel: heatmap representing the protein levels of EGFR, Notch3, and Notch1
obtained by immunohistochemical analysis (IHC) in a cohort of 18 TNBC patients. The colors represent positive (red) or negative (blue) protein levels
according to protein expression cutoff (see Materials and Methods section). Lower panel: summary of the Notch3-EGFR and Notch1-EGFR protein
expression levels correlation showing percentage of each category calculated on the precedent category of patients. c Pattern of immunostaining in
two different cases of TNBC. In case 1 (upper panels), there is a strong and diffuse staining of neoplastic cells both for EGFR (A) and Notch3 (B),
whereas Notch1 is completely negative (C). In case 2 (lower panels), the neoplastic cells are negative for both EGFR (D) and Notch3 (E), whereas
Notch1 (F) shows a weak positivity in about 20% of the cells
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panels), representative of the larger dataset. These data
indicate that in a consistent proportion of TNBC-bearing
patients (about 23%) the presence of EGFR coexists with
NOTCH3 gene expression, allowing us to hypothesize a
possible direct relationship between EGFR and Notch3 at
the protein level in TNBC. To test this hyphotesis, we
then analyzed the pattern of immunohistochemical
expression of Notch3, Notch1, and EGFR in tissue sam-
ples of 18 human TNBCs. In the majority of cases (15/18),
we found EGFR positivity in neoplastic cells. Notch3 is
expressed in a higher percentage of EGFR-positive tumors
as compared with Notch1 (93% vs. 53%) (Fig. 1b, lower
panel). Figure 1c (case 1) shows an example of TNBC
tumor expressing both EGFR (panel a) and Notch3 (panel
b) but not Notch1 (panel c), representative of 6 out of 15
TNBC EGFR+ tissue samples analyzed. Interestingly, two
out of three TNBC samples not expressing EGFR are also
Notch3 negative but express Notch1 (Fig. 1c, case 2), thus
reinforcing the relevant Notch3-EGFR direct correlation
in this cancer subtype.
Notch3 inhibition by siRNA sensitizes TNBC cells to EGFR-
TKI-GEF treatment
To examine whether Notch3 could be involved in the
mechanism of resistance to EGFR TKI, we ﬁrst selected a
group of TNBC cells expressing EGFR at various levels
and known to be EGFR-TKI-resistant cells27,28, and then
we analyzed the expression of both Notch3 and Notch1
proteins (Supplementary Figure S1a). Almost all TNBC
cells expressed activated Notch1 and/or Notch3 protein
(N3IC), thus conﬁrming the hyperactivation of Notch
signaling observed in this BC subtype14, mainly involving
the upregulation of N3IC expression, as it appears at
undetectable levels in MCF10A, a normal immortalized
mammary epithelial cell line. This also occurs in MDA-
MB-453 cells, which express lower EGFR expression (data
not shown) (Supplementary Figure S1a).
As drug resistance commonly involves several
mechanisms that are often closely interconnected with
their genetic proﬁle, for our next analysis we chose the
MDA-MB-468 and BT-549 cells, as they show a “similar”
genetic background (i.e., phosphatase and tensin homolog
(PTEN), RB1, and P53 mutations)29, which could help us
to predict a “similar” sensitivity to TKIs27. We ﬁrst eval-
uated whether the knockdown of Notch3 (siN3) or
Notch1 (siN1) by small interfering RNA (siRNA) could
affect cell growth or viability in such cells (Fig. 2a, d).
Notably, both MDA-MB-468 (Fig. 2a) and BT-549 (Fig.
2d) cells display a more signiﬁcant cell growth reduction
after the selective depletion of Notch3 with respect to
Notch1, measured by counting cell number until 6 days
from the starting point, day 0 thus conﬁrming previous
data14. This effect could be due to the growth arrest of the
cells, as the absence of Notch3 in both cell lines correlates
Fig. 2 Notch3 downregulation by siRNA affects TNBC cells survival. a, d Analysis of cell growth after 0–3–6 days of Notch3 and Notch1 silencing
in a MDA-MB-468 and d BT-549 cells. b, c Whole cell extracts from a MDA-MB-468 or d BT-549 cells at 6 day of silencing were used for western blot
against Notch3 (N3IC) and Notch1 (N1IC), to control the efﬁciency of the b, e Notch3 and c, f Notch1 silencing, respectively. Extracts were then
immunoblotted with anti-p27, anti-cyclin D1, and anti-cyclin D3 antibodies. Anti-β-actin was used as a loading control. b, c, e, f are representative of
three separate experiments. The statistical analysis associated is available in the Supplementary Figure S2
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with a signiﬁcant upregulation of the cyclin-dependent
kinase inhibitor p27Kip1 and downregulation of both the
cyclins D1 and D3, known to be important protein reg-
ulators that exhibit dynamic changes during the cell cycle
(Fig. 2b, e and Supplementary Figure S2a and c). Notably,
the Notch1 silencing does not correlate with any sig-
niﬁcant changes of the same cell cycle regulators analyzed
(Fig. 2c, f and Supplementary Figure S2b and d). These
results demonstrate a speciﬁc role of Notch3 in the reg-
ulation of TNBC cell growth, as conﬁrmed by the absence
of viability of MDA-MB-468 clones stably deleted for
NOTCH3 (but not for NOTCH1), generated by using
genome-editing CRISPR/Cas9 technique (data not
shown).
Previous studies suggested that selective Notch3 inhi-
bition (rather than pan-Notch inhibition) combined with
EGFR TKI therapy should be explored as a novel strategy
in the treatment of lung cancer patients21. In keeping with
these data, we observed that Notch3 silencing signiﬁcantly
enhances the geﬁnitib (GEF)-induced growth inhibition in
both MDA-MB-468 and BT-549 cells (Fig. 3a, c, left
panels: compare siCTR+GEF vs. siN3+GEF), in a
similar or even more extensive way observed after com-
bined treatment with GSI plus TKI-GEF (Supplementary
Figure S3a and b, left panels: compare siCTR+GEF vs.
GSI+GEF). These data thus strongly suggests that
Notch3 depletion rather than pan-Notch inhibitor is
sufﬁcient to sensitize TNBC to TKI-GEF (Fig. 3a vs.
Supplementary Figure S3a; Fig. 3c vs. Supplementary
Figure S3b, left panels: compare siN3+GEF vs. GSI+
GEF). The quality of Notch(s) silencing were monitored
until 6 days by evaluating the expression of both Notch3
and Notch1 proteins (Fig. 3 and Supplementary Figure S3,
all the right panels).
In addition, although Notch1 silencing does not induce
any signiﬁcant changes in BT-549 GEF-treated cells with
respect to control cells (Fig. 3d, compare siCTR+GEF vs.
siN1+GEF), it seems to paradoxically increase the MDA-
MB-468 cell growth in response to GEF (Fig. 3b, left
panel: compare siCTR+GEF vs. siN1+GEF). These data
suggest a potential different role of the different Notch
receptors expressed in the same TNBC context relative to
the TKI-response, which remains to be fully elucidated.
Dual targeting of EGFR and Notch3 increases both EGFR
internalization and dephosphorylation, and decreases the
EGFR nuclear localization
To understand how the Notch3-dependent TKI resen-
sitization observed above could occur in TNBC cells, we
initially examined whether EGFR turnover could be
inﬂuenced by the absence of Notch3 rather than Notch1.
To this purpose we focused our next studies on MDA-
MB-468 cells, by evaluating both the EGFR subcellular
localization and its tyrosine phosphorylation status, which
is essential for EGFR to activate downstream mitogenic
pathways and represents the basis for targeted therapy
with TKIs30.
The MDA-MB-468 cells were treated with GEF, alone
or in combination with Notch3 or Notch1 silencing (siN3
+GEF or siN1+GEF, respectively) for 6 days, followed
by the analysis of the following: (1) the EGFR surface
expression (EGFREC) by ﬂuorescence-activated cell sort-
ing (FACS) analysis (Figs. 4a) and (2) the tyrosine-
phosphorylated EGFR expression at 1173 residue (pEG-
FRY1173) in both whole cell (Fig. 4b) and nuclear extracts
(Fig. 4c). Notably, the absence of Notch3 amplifyies the
GEF-dependent decrease of EGFREC surface-expressing
cells (siN3+GEF: 54,4% vs. GEF: 66,9%) (Fig. 4a, left
panels) whereas Notch1 silencing does not (siN1+GEF:
69% vs. GEF: 70%) (Fig. 4a, right panels). Similarly,
Notch3 depletion leds to a signiﬁcant decrease of pEG-
FRY1173 expression, which appears rarely detectable in
both total and nuclear extracts of GEF-treated Notch3-
silenced cells (Fig. 4b, c, left panels, respectively). On the
contrary, Notch1 silencing does not induce important
alterations of pEGFRY1173 expression neither in whole cell
nor in nuclear extracts from GEF-treated cells (Figs. 4b, c,
right panels, respectively). It has been reported that the
full-length form of nuclear EGFR is involved in several
mechanisms including cell proliferation31. Consistent
with this, by measuring bromodeoxyuridine (BrdU)-
positive cells during the combined experiments (after
4 days), we observed a signiﬁcant decrease in the per-
centage of cells entering the S phase in GEF-treated
Notch3-silenced cells with respect to GEF-treated cells
(Fig. 4d, compare siCTR+GEF vs. siN3+GEF). Notably,
in keeping to what is shown above (Fig. 3b), we observed
an increase in the percentage of proliferative GEF-treated
Notch1-silenced cells with respect to their counterpart
treated with GEF alone (Fig. 4e, compare siCTR+GEF vs.
siN1+GEF).
All these data suggest an important correlation between
EGFR behavior and Notch3 receptor in TKI-response of
TNBC cells, thus providing a rationale for a combined
therapy approach with TKI-GEF and Notch3 inhibition.
Rafts depletion correlates with EGFR dephosphorylation by
PTPH1 phosphatase in TKI-resistant TNBC cells
In order to further understand the molecular mechan-
ism underlying the EGFR-Notch3 crosstalk in TNBC, we
investigated in more detail whether and how Notch3 may
be involved in the regulation of the above described
processes of EGFR subcellular localization and its phos-
phorylation/activation status.
It has been shown that EGFR localizes within lipid rafts
in different cell lines32 and this speciﬁc localization could
induce different functional effects33,34. More recently,
Irwin et al.35 have shown that EGFR localization to lipid
Diluvio et al. Oncogenesis  (2018) 7:42 Page 5 of 15
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rafts of TNBC cells may correlate with their resistance to
EGFR TKI-induced growth inhibition. First, we conﬁrmed
the presence of EGFR within lipid rafts by using bio-
chemical and confocal microscopy analyses: Fig. 5a shows
that EGFR (green) strongly colocalizes with GM1 (red), a
lipid raft glycosphingolipid speciﬁcally recognized by the
Cholera toxin subunit B. Biochemical rafts isolation
shown in the Fig. 5b conﬁrms these data. Notably, the
tyrosine-pEGFR expression, essential for its functional
activity36 and predictive for target therapy efﬁciency with
TKIs30 appears to be exclusive of raft compartment, as it
moved to the non-rafts fractions in the presence of
Methyl-β-cyclodextrin (MβCD), a drug which removes
cholesterol from the plasma membrane, thus disrupting
the integrity of membrane rafts microdomains (Fig. 5b).
Interestingly, after MβCD treatment, we observe a clear
defect in the increase of EGF-induced tyrosine phos-
phorylation of EGFR at 1173 residue (pEGFRY1173) but
not at 1068 residue (pEGFRY1068) (Fig. 5c), thus suggest-
ing the presence of potential different roles between
EGFR phosphorylation pattern and function of different
tyrosine phosphorylation sites30. These data indicate a
Fig. 3 Notch3 downregulation (but not Notch1) sensitizes TNBC cells to TKI-geﬁtinib. a–d Left panels: inhibition of a, b MDA-MB-468 and c, d
BT-549 cell growth was observed after geﬁtinib (GEF) treatment combined with Notch3 silencing in a, c but not with b, d Notch1 silencing. All the
right panels showed in the ﬁgure represent western blotting of total extracts from cells described above against Notch3 (N3IC) and Notch1 (N1IC), to
control the efﬁciency of the a, c Notch3 and b, d Notch1 silencing, respectively. Anti-β-actin was used as a loading control. All data are representative
of at least three independent experiments, each in triplicate. Results shown in a, b, c, and d are expressed as the means average deviations and P-
values were calculated using Student’s T-test (i.e., ns not signiﬁcant; P > 0.05, *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001)
Fig. 4 Combined Notch3 and EGFR targeting induces EGFR internalization but defect the nuclear-activated EGFR localization. a FACS
analysis of the EGFR surface expression (EGFREC) in MDA-MB-468 cells treated with geﬁtinib (GEF) alone or in combination with Notch3-silencing
(siN3+ GEF) or Notch1 silencing (siN1+ GEF) for 6 days. b Whole cell extracts (WCE) and c nuclear extracts from the same cells used in a were
immunoblotted with anti-EGFR and anti-pEGFR(Y1173) antibodies, to evaluate the EGFR expression and phosphorylation, and with anti-N3IC or anti-
N1Val1744 antibody to control the efﬁciency of Notch3 (left panels) or Notch1 (right panels) silencing, respectively. Anti-lamin B and anti-tubulin were
used as fraction markers; anti-β-actin was used as a loading control. d, e Proliferation analysis by BrdU assay (see Matherials and Methods section):
compared with control cells (siCTR+ GEF), the percentage of BrdU+ cells is lower after Notch3 silencing plus d GEF (siN3+ GEF) and not after
Notch1 silencing plus e GEF (siN1+ GEF). All data are representative of at least three independent experiments, each in triplicate. Results are
expressed as the means average deviations and P-values were calculated using Student’s T-test (i.e., *P ≤ 0.05)
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Fig. 5 Rafts depletion induces endogenous EGFR-PTPH1 interaction, EGFR dephopshorylation, and its intracellular arrest in MDA-MB-468
TNBC cells. a Immunoﬂuorescence assay (IF) was performed by using anti-EGFR (green) and anti-GM1 (red) antibodies to reveal the endogenous
EGFR-rafts colocalization, shown in yellow (merge). Nuclei were DAPI labeled (blue). b Raft (R) and non-raft (NR) fractions derived from Methyl-β-
cyclodextrin (MβCD)-treated and untreated cells were used for immunoblot assay with anti-pEGFR(Y1173) (indicated as pEGFR) and anti-EGFR
antibodies, to test activated and total EGFR expression in rafts compartment, respectively. Anti-transferrin and anti-GM1 antibodies were used as a
fraction markers. c Cells have been activated with EGF ligand for the times indicated, in the presence or absence of MβCD: the expression of
phospho-EGFR at tyrosine 1173 and 1068 residues and total EGFR was determined in whole cell extracts by immunoblot analysis using the speciﬁc
indicated antibodies. d–f MDA-MB-468 cells were treated with MβCD and stimulated with EGF for 60 min: control or anti-PTPH1 antibody
immunoprecipitates were probed with anti-EGFR, to detect the EGFR-PTPH1 binding, and with the anti-PTPH1 antibody, to show PTPH1
immunoprecipitated protein levels. The inputs indicated in the panel shows 5% of each total lysate d. Relative EGFR extracellular expression (EGFREC)
was evaluated by FACS e. IF assay was performed by using anti-EGFR (red) antibody to reveal the endogenous EGFR intracellular localization. Nuclei
were DAPI labeled (blue). White arrows indicated peri-nuclear EGFR localization in EGF stimulated MβCD-treated cells (f). a, f Representative single
plane confocal IF images captured using a × 60 oil objective. Scale bar: 10 μm. In both b and c, western blotting against the anti-β-actin was used as a
loading control. All data are representative of at least three independent experiments, each in triplicate. Results shown in e are expressed as the
means average deviations and P-values were calculated using Student’s T-test (i.e., ns, not signiﬁcant P > 0.05, **P ≤ 0.01)
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possible relationship between rafts compartment integrity
and EGFR/Y1173 dephosphorylation, which is known to
have an important role in the therapeutic activity of EGFR
TKI inhibition through the involvement of the tyrosine
phosphatase H1 (PTPH1)37.
Several protein tyrosine phosphatases (PTPs) depho-
sphorylate EGFR at Y1173 (alone or together with other
residues)38,39. Among them, the PTPH1 speciﬁcally cata-
lyzes EGFR/Y1173 dephosphorylation (and not EGFR/
Y1068 dephosphorylation), thus ﬁnally increasing non-
TNBC BC sensitivity to TKIs, including GEF37. The
EGFR/PTPH1 direct interaction is closely required to
favor the therapeutic targeting of EGFR itself37. In
agreement with this, we observed that MβCD-treated
TNBC cells showed high levels of endogenous EGFR-
PTPH1 interaction (Fig. 5d), thus suggesting the possible
PTPH1 involvement in the observed decreased levels of
EGFR/Y1173 phosphorylation after rafts depletion (Fig.
5c). Interestingly, the EGFR-PTPH1 interaction dis-
appears after MβCD plus EGF ligand (Fig. 5d), probably
due to the EGF-dependent endocytic events of ligand-
activated EGFRs which may inﬂuence the kinetics of
EGFR availability to PTPs-mediated dephosphorylation40.
In keeping with this, we observed a decreased extra-
cellular EGFR expression (EGFREC) in MβCD-treated
cells with respect to untreated cells, upon stimulation
with EGF (Fig. 5e), despite the natural slowdown of EGFR
endocytic trafﬁcking in MDA-MB-468 cells due to their
known saturated endocytic machinery41. In agreement
with previous data42, our results suggest that rafts
depletion may allow the internalization of ligand-
occupied EGFR. Following ligand binding and receptor
phosphorylation/activation, pEGFR is endocytosed and
commonly transported to lysosome where it is degra-
ded43. In our experiments, we do not observe decreased
levels of total EGFR expression after rafts depletion (Fig.
5c, d), thus suggesting that removal of EGFR from the cell
surface observed in MβCD-treated cells may be correlated
to a different mechanism of EGFR downregulation, not
involving receptor degradation. Since it has been
demonstrated that many tumor cells which overexpress
EGFR, including the MDA-MB-468 cells, have limited
ligand-stimulated EGFR degradation44 and that tyrosine
dephosphorylation of EGFR is correlated with an
increased EGFR stability37, we wanted to know where the
EGFR accumulated after MβCD treatment, in order to
completely understand how signaling by the EGFR is
terminated. To this purpose, cells were treated with or
without MβCD and stimulated with EGF ligand for
60min, followed by the immunostaining with anti-EGFR
antibody (Fig. 5f): confocal analysis shows that rafts
depletion correlates with the accumulation of EGFR at a
peri-nuclear level (white arrows) whereas the majority of
MβCD-untreated cells (EGF stimulated) show spots of
nuclear EGFR, which represents a speciﬁc localization
known to be associated with resistance to EGFR-targeted
therapies31. In addition, the same control cells stimulated
with EGF ligand show persistent high levels of EGFR
cell surface expression (Fig. 5f), thus conﬁrming the
saturation of the endocytic machinery previously
mentioned41.
Together, these data indicate that EGFR trafﬁcking is
retained outside the nucleus in MDA-MB-468 TNBC cells
in response to the rafts-disrupting agent, MβCD.
Notch3 inhibition by siRNA mimics rafts depletion effects
on EGFR in TKI-resistant TNBC cells
We have previously shown that Notch3 receptor con-
stitutively localizes to lipid rafts of Notch3 overexpressing
lymphocytes, thus contributing to sustain the signaling
pathways responsible of the T-cell leukemia develop-
ment45. Here we ﬁrst hypothesized that both Notch3 and
EGFR receptors could share the same localization to
directly interact, leading to the observed EGFR-TKI
resistance process in TNBC cells. Surprisingly, both
confocal analysis (Supplementary Figure S4a, upper
panels) and biochemical rafts isolation with or without
MβCD treatment (Supplementary Figure S4b) show that
in MDA-MB-468 cells Notch3 receptor (N3EC) is widely
expressed in all the cell surface, whereas Notch1 receptor
appears to be restricted to lipid rafts microdomains
(Supplementary Figure S4a, lower panels, and S4b). Thus,
Notch3 and EGFR do not completely colocalize (Supple-
mentary Figure S4c, upper panels), whereas Notch1 shows
a strong rafts colocalization with EGFR (Supplementary
Figure S4c, lower panels). Notably, by in situ proximity
ligation assay (PLA), we still observed the endogenous
Notch3/EGFR complex all around the cell membrane
(Supplementary Figure S4d) while Notch1/EGFR complex
seems to be mainly restricted to a limited portion of the
membrane (Supplementary Figure S4e), reﬂecting their
strictly shared localization (Supplementary Figure S4c,
lower panels).
These results suggest the existence of a different rela-
tionship between Notch3 or Notch1 and EGFR in TNBC.
However, in order to deepen inside the molecular
mechanism related to the TKI-GEF resensitization of
TNBC cells observed only when Notch3 (and not Notch1)
is depleted (Fig. 3), here we further investigated how the
EGFR-rafts localization could be inﬂuenced when Notch3
is depleted. Similar to what happens in MβCD-treated
cells (Fig. 5b-d), in the absence of Notch3 the tyrosine
phosphorylation of EGFR at 1173 residue (pEGFRY1173)
disappears and this event does not involve receptor
degradation, as EGFR total levels remain unchanged (Fig.
6a). Notably, after Notch3 depletion, we observed a clear
defect in the increasing levels of EGF-induced tyrosine
phosphorylation of EGFR at 1173 residue (pEGFRY1173)
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but not at 1068 residue (pEGFRY1068) (Fig. 6b), as already
shown after rafts depletion (Fig. 5c). For this reason, we
further investigated whether Notch3 could inﬂuence the
EGFR/Y1173 dephosphorylation by the phosphatase
PTPH1, by using co-immunoprecipitation assay. In
agreement with the above results (Fig. 5d), we observed
that the absence of Notch3 is able to induce the endo-
genous EGFR/PTPH1 interaction (Fig. 6c), thus suggest-
ing a possible link between Notch3, EGFR-rafts
localization and EGFR dephosphorylation event by
PTPH1.
In addition, we also observed that the absence of
Notch3 correlates with a rapid and persistent EGFR
downregulation from the cell surface, as revealed by the
decrease of EGFREC mean ﬂuorescence intensity (MFI) in
Notch3-depleted cells (siN3) with respect to control cells
(siCTR) after EGF stimulation (Fig. 7a, upper panel). As
expected, treatment of MDA-MB-468 cells with EGF until
270min results in an increased EGFR surface expression
(Fig. 7a, upper panel), also supported by the unchanged
levels of total EGFR protein (Fig. 7a, lower panels), as
previously reported (Fig. 5f and41). Interestingly, despite
the increased EGFR internalization observed in the
absence of Notch3, although the pEGFRY1173 expression
decreases, the EGFR total levels does not change, thus
suggesting that Notch3 depletion (such as rafts depletion)
could correlate with an increased dephopshorylated EGFR
endocytosis followed by its intracellular shuttling block-
ade rather than sorting for intracellular degradation.
Using immunoﬂuorescence staining, we obtained addi-
tional evidence in support of the Notch3-depletion
dependence of EGFR intracellular fate. As shown in the
Fig. 7b, after 2 h of EGF stimulation combined with
Notch3 silencing, we observed that EGFR localizes pre-
ferentially at a peri-nuclear level, similarly to what
observed after MβCD treatment (Fig. 5f). Interestingly, a
few cells show a similar EGFR staining also without EGF
stimulation (Fig. 7b, see white arrows), thus suggesting
that Notch3, alone, may inﬂuence the EGFR internaliza-
tion also through ligand-independent mechanisms (data
not shown).
Together these results demonstrate that Notch3
depletion mimics the effects of rafts depletion on EGFR,
as the Notch3 silencing correlates with EGFR depho-
sphorylation (by PTPH1) and its persistent internaliza-
tion, followed by intracellular arrest.
Fig. 6 Notch3 downregulation induces EGFR dephosphorylation by promoting the endogenous EGFR/PTPH1 interaction. a Raft (R) and
non-raft (NR) fractions derived from 6 days of Notch3-silenced cells were used for immunoblot assay with anti-N3EC, anti-pEGFR(Y1173), and anti-EGFR
antibodies, to test the effect of Notch3 downmodulation on EGFR-rafts localization. Anti-transferrin and anti-GM1 were used as a fraction markers. b
Cells have been activated with EGF ligand for the times indicated, combined or not with Notch3 silencing for 3 days: the expression of phospho-
EGFR at tyrosine 1173 and 1068 residues and total EGFR was determined by immunoblot analysis using the speciﬁc indicated antibodies. c Control or
anti-PTPH1 antibody immunoprecipitates from control and Notch3-silenced cells were probes with anti-EGFR, to detect the EGFR-PTPH1 binding, and
with the anti-PTPH1 antibody, to show PTPH1 immunoprecipitated protein levels. The inputs indicated in the panel shows 5% of each total lysate
(right panels). Whole cell extracts (WCE) were incubated with anti-N3IC antibody to control the efﬁciency of Notch3 silencing (left panels). In all panels
a, b and c, western blotting against the anti-β-actin was used as a loading control. The results are representative of three independent experiments
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Discussion
Among the EGFR TKIs, GEF and erlotinib were the ﬁrst
to be approved by Food and Drug Administration for
treatment of NSCLC46. These drugs inhibit the EGFR
kinase activity, ﬁnally resulting in proliferation inhibition,
cell cycle progression delay, and apoptosis47. Although
EGFR TKIs show good response rates and progression
free survival in NSCLC patients with EGFR gene muta-
tions, acquired resistance to TKIs therapy is commonly
reported, often due to multiple mechanisms including
EGFR additional mutations48,49, activation of redundant
kinase signaling pathway, or EGFR downstream mole-
cules2. As activating mutations of EGFR in BC are rare, it
is uncertain whether some of the above mentioned
mechanisms observed in NSCLC are involved in the
failure of clinical trials with TKIs in TNBC. One possible
explanation for the lack of response to current targeted
therapies is that most TNBCs are not exclusively depen-
dent on EGFR signaling for their survival but involve the
activation of alternative receptors and pathways. As some
NSCLC patients with wild-type EGFR gene ampliﬁcation
and wild-type KRAS also respond to EGFR TKIs50, it may
be that these alternative resistant pathways need to be
blocked in wild-type EGFR overexpressing TNBC patients
to increase TKIs therapy efﬁcacy.
Here we demonstrate that Notch3 (but not Notch1) is
strongly involved in the TNBC resistance to TKIs, as
Notch3 depletion induces the resensitization of TNBC
cells to GEF treatment. These results indicate that
Notch3 speciﬁcally functions in these cells without
invoking contributions from other Notch receptors,
thus supporting the importance of a selective Notch3
therapeutic targeting in order to avoid the known
toxicity associated with pan-Notch inhibition51. The
signiﬁcant correlation observed between Notch3 and
EGFR in a large group of human TNBC patients supports
these data.
Mechanistically, we show that Notch3 depletion induces
the downregulation of EGFR cell surface expresssion and
function by promoting its dephosphorylation via PTPH1
and its intracellular arrest, similar to what observed after
rafts-disrupting treatments. Interestingly, we have shown
that MDA-MB-468 TNBC-resistant cells show a strong
lipid rafts localization of the activated EGFR. In addition,
it has been demonstrated that EGFR overexpression
correlates with the natural saturation of its endocytic
trafﬁcking41. Consequently, in these cells EGFR seems not
to be available to be downregulated, thus ﬁnally retaining
a constitutive higher surface expression, known to be
associated with cell growth44. In this scenario, the
Notch3 silencing is able to favor a hypothetical shift of
the EGFR from rafts to non-rafts compartment, thus
moving it to a membrane localization, which may be
available to subsequent downregulating events. Possible
Fig. 7 Notch3 downregulation induces EGFR internalization and
intracellular arrest. a Upper panel: FACS analysis of the EGFR surface
expression (EGFREC) in control (siCTR) and Notch3-silenced (siN3) cells
after EGF stimulation for the time indicated, shown as percentage of
the mean ﬂuorescence intensity (MFI) respect to the EGF-untreated
cells (t= 0). lower panel: Western blot analysis of the total extracts
from the same cells probed with anti-Notch3 (N3IC) antibody, to test
the efﬁciency of Notch3 silencing, and with anti-EGFR and anti-
pEGFR(Y1173) antibodies, to evaluate the EGFR expression. The β-actin
expression was used as loading control. b MDA-MB-468 cells were
Notch3-silenced for 48 h and EGF-treated for 2 h:
Immunoﬂuorescence assay (IF) was performed by using anti-Notch3
green) or anti-EGFR (red) antibodies to test the efﬁcacy of
Notch3 silencing and to reveal the endogenous EGFR intracellular
localization, respectively. Nuclei were DAPI labeled (blue). EGFR/DAPI
merge is shown. White arrows indicate peri-nuclear EGFR localization
in Notch3-silenced cells. The * indicate the higher magniﬁcation of a
single EGF-stimulated control cell (left) and Notch3-silenced (right)
cell. All the panels are representative single plane confocal IF images
captured using a × 60 oil objective. Scale bar: 10 μm. The results are
representative of three independent experiments
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mechanisms able to attenuate EGFR signaling include
dephosphorylation of the EGFR, removing it from the cell
surface and allowing degradation of the receptor or
sequestration into intraluminal vesicles52. PTPH1 is a
phosphatase able to speciﬁcally dephosphorylate EGFR at
tyrosine Y1173 residue53, thereby regulating EGFR inter-
action with ER and the subsequent ER+ BC sensitivity to
TKIs treatment37. In both Notch3-silenced and MβCD-
treated cells, we observed a strong EGFR-PTPH1 endo-
genous interaction which is correlated with a signiﬁcant
decrease of pEGFRY1173 expression, thus suggesting that
EGFR dephosphorylation by PTPH1 may represent an
important event of the observed Notch3-dependent
increased response to TKI-GEF. Further studies are
required to understand if PTPH1 could be recruited into
lipid rafts before EGFR moving, as PTPH1 is involved in
the non-clathrin endocytosis of EGFR in lung cancer54
and/or if the EGFR internalization is required for the
PTPH1-EGFR interaction, as occurs for other tyrosine
phosphatases function on EGFR itself55.
EGFR dowregulation commonly involves a clathrin-
mediated endocytosis event dependent on physiological
concentrations of growth factors42. Moreover, it has been
demonstrated that EGFR internalization occurs also
under various stress conditions (such as treatment with
drugs) through the involvement of p38 mitogen-activated
protein kinase (MAPK), ﬁnally leading to its arrest in
endosomes, without recycling56. Here we demonstrate
that Notch3 depletion induces an increased EGFR inter-
nalization, more evident in combination with GEF, thus
leading to the EGFR intracellular accumulation and not
degradation. Interestingly, Notch3 is able to positively
control the levels of MAPK phosphatase 1 (MKP-1), thus
decreasing the levels of phosphorylated p38, a canonical
MKP-1 target57. These data suggest that the absence of
Notch3 may mimic a stress condition able to activate p38
and favor the EGFR non-canonical internalization.
Moreover, it has been also shown a direct crosstalk
between PTPH1 and p38 MAPK in promoting Ras
oncogenesis and regulating stress response: in particular,
PTPH1 represents a p38γ-speciﬁc phosphatase58 and
PTPH1 phosphorylation by p38 is required to favor the
PTPH1 dephosphorylation activity on its targets, such as
EGFR/Y117353. These observations further support our
hypothesis of an important involvement of Notch3-
PTPH1 axis in the regulation of EGFR internalization
machinery in TNBC. Moreover, the EGFR intracellular
accumulation observed in Notch3-depleted cells corre-
lated with a defect in its nuclear localization, further
suggesting that removal of EGFR from the cell surface
may help to evade survival signaling and enhances drug-
induced cell death, in accordance with a previous report42.
Collectively, our data suggest an important role of
Notch3 in regulating the EGFR subcellular localization
and function in TNBC cells, thus contributing as an
intrinsic resistant factor to anti-EGFR therapies, whose
failure is often dependent on different EGFR subcellular
localization that elicit distinctly different and also over-
lapping signals35,59 and can make the receptor unavailable
to be targeted.
Due to the heterogeneity of the TNBC and its poor
outcome, subtyping through robust predictive and prog-
nostic biomarkers that may contribute to therapy resis-
tance is crucial for understanding the molecular
mechanism underlying EGFR inhibitors sensitivity and
further discuss the possible perspective on anti-EGFR
therapies in TNBCs. In this view, here we observed an
overlapped TKI-response in MDA-MB-468 and BT-549
cell lines, which both express a constitutive EGFR acti-
vation in a PTEN-null background, that is a known
common combination of aggressive and drug-resistant
subset of TNBC60. Based on our results, we can suggest
Notch3 as one driver of an oncogenic signaling network,
which may inﬂuence this intrinsic EGFR-TKI drug
resistance in TNBC cells with such a similar molecular
signature, ﬁnally allowing the design of speciﬁc
target therapy protocols, which may include Notch3
inhibition as a potential approach for overcoming TKIs
resistance.
Materials and methods
Cell culture and treatments
Human BC MDA-MB-468, MDA-MB-231, HCC1143,
and BT-549 TNBC cell lines were obtained from ATCC;
HCC38, BT-20, HS578T, and MDA-MB-453 TNBC cell
lines were kindly provided by Professor JV Olsen (Novo
Nordisk Foundation Center for Protein Research, Uni-
versity of Copenhagen, Denmark). All TNBC cells were
maintained in accordance with the ATCC’s instructions
and all are mycoplasma free.
Cell viability was measured by the Trypan blue dye
exclusion assay (Sigma-Aldrich, St Louis, MO, USA,
Catalog number T8154). Cells were treated with the fol-
lowing compounds: 5 mM MβCD (Sigma-Aldrich, Cata-
log number C4555); 3 μM GEF (Iressa, Selleckem,
Houston, TX, USA; Catalog number ZD1839), 100 nM
EGF Ligand (EGF; Gibco, Life Technologies, Carlsbad,
CA, USA; Catalog number PHG0315); 10 μM of GSI IX
(DAPT) (Calbiochem, Darmstadt, Germany; Catalog
number 565770).
siRNA silencing
Cell were transfected as previously described61 with
siRNAs anti-Notch3 (Catalog number sc-37135),
Notch1 (Catalog number sc-36095), and corresponding
control scrambled siRNAs (Catalog number sc-37007),
all from Santa Cruz Biotechnology (Santa Cruz, Dallas,
TX, USA).
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Protein extract preparation, immunoprecipitation, and
immunoblot analysis
Protein extract preparation62, immunoprecipitation
assay63, immunoblotting assays64, and sucrose gradient
for rafts isolation45 were performed as described else-
where. Primary antibodies were as follows: anti-Notch3
(Catalog number 2889), anti-Notch1 (Catalog number
2421), anti-activated Notch1 (N1Val1744), anti-EGFR
D38B1 (Catalog number 4267S), anti-phospho-EGFR
Y1173 (53A5-Catalog number 4407S), and anti-
phospho-EGFR Y1068 (Catalog number 2234S), all from
Cell Signaling (Danvers, MA, USA); anti-α-tubulin (Cat-
alog number sc-8035), anti-Lamin B M20 (Catalog num-
ber sc-6217), anti-p27 C19 (Catalog number sc-528), anti-
cyclin D1 M20 (Catalog number sc-718), anti-cyclin D3
C16 (Catalog number sc-182), anti-Notch1 L18 (N1EC)
(Catalog number sc-23299), anti-transferrin H65 (Catalog
number sc-21011), and anti-PTPH1 (Catalog number sc-
515181), all from Santa Cruz Biotechnology; anti-β-actin
(Catalog number A5441) and anti-cholera toxin B subunit
peroxidase conjugate (GM1, Catalog number C3741)
from Sigma-Aldrich; and anti-Notch3 5E1 (N3EC) anti-
body was kindly provided by Professor A Joutel65.
Immunoﬂuoresce assay and confocal imaging
Immunoﬂuorescence staining and in situ PLA were
performed as described elsewhere66. Primary antibodies
were as follows: rabbit anti-Notch3 M-134 (Catalog
number sc-5593), mouse anti-EGFR 528 (Catalog number
sc-120), and rabbit anti-Notch1 L18 (Catalog number sc-
23299) from Santa Cruz Biotechnology; anti-GM1 (Life
Technologies; 595-Cy3 conjugated, Catalog number
C34777); mouse anti-Notch3EC, Clone 1E4 (Millipore,
Billerica, MA, USA; Catalog number MABC594); and
rabbit anti-EGFR (Proteintech, Rosemont, IL, USA; N-
Terminal, Catalog number 22542–1-AP). Secondary
antibodies were as follows: Alexa Fluor 594- and 488-
conjugated, respectively, both anti-mouse and anti-rabbit
(Molecular Probes, Life Technologies). Nuclei were
counterstained with Hoechst reagent. Single, plane con-
focal images in the center of the cell were acquired using
an inverted Olympus iX73 microscope equipped with an
X-light Nipkow spinning-disk head (Crest Optics, Rome,
Italy) and Lumencor Spectra × Led illumination. Images
were collected using a CoolSNAP MYO CCD camera
(Photometrics, Tucson, AZ, USA) and MetaMorph Soft-
ware (Molecular Device, Sunnyvale, CA, USA) with a × 60
oil objective.
Immunohistochemistry
Studies on human samples (already obtained for
diagnostic purposes) were performed according to the
standards of the local ethical committee. Immunois-
tochemistry was performed as previously described11, by
using the following antibodies: anti-Notch1 C-20R (Santa
Cruz Biotechnology; Catalog number sc-6014, 1:50 dilu-
tion), anti-Notch3 M-134 (Santa Cruz Biotechnology;
Catalog number sc-5593, 1:50 dilution), and anti-EGFR
D38B1 (Cell Signaling; Catalog number 4267S, 1:50
dilution). The sample was deﬁned as negative when the
number of stained cells was < 1% of the tumor cell
population. The percentage of positive cells for each
marker analyzed is reported in the Figure.
In vitro BrdU assay and FACS analysis
In vitro BrdU assay was performed as described else-
where67. For EGFREC expression, cells were stained with
anti-EGFR antibody (Santa Cruz Biotecnology; Catalog
number sc-528) or normal mouse IgG (Santa Cruz Bio-
tecnology; Catalog number sc-2025) used as a negative
control. Data were analyzed on a FACS-Calibur with
CellQuest software (BD Bioscience, San Jose, CA, USA),
as previosuly described68.
In silico analysis of TNBC patients’ deposited data
Tumor samples from a cohort of 198 TNBC patients
(GEO ID: GSE76124) and 579 TNBC patients (GEO ID:
GSE31519) were selected and analyzed for the correlation
between NOTCH1 or NOTCH3 and EGFR genes. The
expression values were ﬁltered in each analysis utilizing
the expression probe set 218902_at representing
NOTCH1, 203238_s_at representing NOTCH3, and
201983_s_at representing EGFR. The expression value of
NOTCH1, NOTCH3, and EGFR for both datasets was in
log2 scale after normalization of the data with the RMA
algorithm. The index Pearson’s r coefﬁcient correlation
and reported P-values were calculated using GraphPad
Prism software Version 6.0 (La Jolla, CA, USA) for both
datasets. Plots were generated and data were converted to
standard score for the plots using GraphPad Prism Ver-
sion 6.0.
Statistical analysis
All results were reported as the mean ± SD of at least
three independent experiments, each performed in tri-
plicate. Student’s t-test for unpaired samples was used to
assess differences among groups, with similar variance. A
P-value of 0.05 was considered statistically signiﬁcant (NS
P > 0.05; *P ≤ 0.05; **P ≤ 0.01; ***P ≤ 0.001). We estimated
the sample size considering the variation and mean of the
samples. No statistical method was used to predetermine
sample size. No samples were excluded from any analysis.
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